Thermo Fisher Scientific stock
TMONYSEThermo Fisher Scientific Inc., HealthcareISIN US8835561023
69Score 69 out of 100, Neutral
Price and trend
88 / 100
Price history
+22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is at its 52-week high. Largest decline in 20 years: 54% (August 2008 to November 2008).
Chart figures for advanced users
- SMA 50$667.17
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$554.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$438.34
- The lowest closing price of the last twelve months.
- Resistance$721.63
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Thermo Fisher Scientific Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $265.92B, is the largest of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $44.56B (up 3.9% year on year) and earnings of $6.74B (up 6.3%).
- For fiscal 2026, analysts expect on average revenue of $48B (up 7.7%) and adjusted earnings per share of $25.29 (up 10.6%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 162 of 714 in Healthcare, median 53.
- The P/E is 37.6 (Medical (Diagnostics & Research) median 33.7, own median of recent years 32).
- Our model puts fair value at $574.44, with the price 25% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 14 years.Capital allocation 70
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 84
- Share buybacksShare count down 5% since 2020.Capital allocation 70
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are technical analysis and momentum, while growth and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- very large company
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $441.88 and expensive above $820.64 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $504.74 (cash-flow model) and $644.15 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $535.48, at 8.7% it would be $629.69.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 26 Sep 2026, revenue rose 8.3% on the twelve months before. Revenue has grown strongly since 2006, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 41%, operating 18%, net 15%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 21 Oct 2026EPS reported $6.68 (expected $6.40)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $25.29+0.6%
- Revenue
- $48B+0.2%
- Earnings per share
- $27.74+0.9%
- Revenue
- $50.57B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +7.9%Guidance raised: 2026 revenue of $47.4 billion to $48.1 billion and adjusted EPS of $24.93 to $25.33 (up $0.25 at the midpoint), with organic growth at the upper end of 3% to 4%.
“We now expect revenue to be in the range of $47.4 million to $48.1 billion and adjusted EPS to be in the range of $24.93 to $25.33, now representing 9% to 11% adjusted EPS growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $63.56M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Britt Lisa P.Sale
28 Oct 2026, Sr. VP and Chief HR Officer
- Shares
- 2,831
- Price
- $706.45
- Value
- $2M
- Pettiti GianlucaSale
31 Aug 2026, President & COO
- Shares
- 4,133
- Price
- $614.38
- Value
- $2.54M
- Casper Marc NSale
24 Aug 2026, Chairman & CEO
- Shares
- 275
- Price
- $627.05
- Value
- $172,439
Show 10 more
- Casper Marc NSale
21 Aug 2026, Chairman & CEO
- Shares
- 10,000
- Price
- $626.92
- Value
- $6.27M
- Casper Marc NSale
20 Aug 2026, Chairman & CEO
- Shares
- 10,000
- Price
- $629.27
- Value
- $6.29M
- Britt Lisa P.Sale
19 Aug 2026, Sr. VP and Chief HR Officer
- Shares
- 11,440
- Price
- $613.12
- Value
- $7.01M
- Shafer Michael DSale
11 Aug 2026, Executive Vice President
- Shares
- 25,500
- Price
- $600.00
- Value
- $15.3M
- Holmes Joseph R.Sale
7 Aug 2026, VP & Chief Accounting Officer
- Shares
- 420
- Price
- $584.81
- Value
- $245,620
- Casper Marc NSale
7 Aug 2026, Chairman & CEO
- Shares
- 4,883
- Price
- $586.12
- Value
- $2.86M
- Britt Lisa P.Sale
6 Aug 2026, Sr. VP and Chief HR Officer
- Shares
- 5,850
- Price
- $580.00
- Value
- $3.39M
- Casper Marc NSale
6 Aug 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $574.46
- Value
- $8.62M
- Casper Marc NSale
5 Aug 2026, Chairman & CEO
- Shares
- 15,000
- Price
- $575.23
- Value
- $8.63M
- Pettiti GianlucaSale
27 Jul 2026, President & COO
- Shares
- 400
- Price
- $565.00
- Value
- $226,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Thermo Fisher Scientific
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next smaller companies by market value
- DanaherDHR $165.55B66
- WuXi AppTec603259.SS $67.65B84
- IDEXX LaboratoriesIDXX $55.35B79
- Agilent TechnologiesA $49.89B77
- NateraNTRA $46.38B43
- WatersWAT $46.24B56
- IQVIA HoldingsIQV $45.24B67
- Mettler-Toledo InternationalMTD $35.04B76
ETFs that hold Thermo Fisher Scientific
Held by 106 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 3.81% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 3.80% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 3.74% | 0.15% | €592.11M |
Show 5 more
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 2.73% | 0.25% | €4.18B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.19% | 0.49% | €318.39M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.69% | 0.18% | €837.43M |
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 1.60% | 0.49% | €368.7M |
| iShares Inclusion and Diversity UCITS ETFOPEN | 1.17% | 0.25% | €76.52M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.